Scientists test double and quadruple doses in bid for Longer-Lasting psoriasis relief
Disease control
Completed
This small, completed study tested whether starting treatment for moderate-to-severe plaque psoriasis with double or quadruple the standard dose of the drug risankizumab could lead to better and longer-lasting skin clearance. Researchers wanted to see if these higher doses more e…
Phase: PHASE2 • Sponsor: Oregon Medical Research Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC